Recent Quotes (30 days)

You have no recent quotes
chg | %

Dechra Pharmaceuticals plc news

   Watch this stock
Showing stories 1 - 10 of about 81   

Articles published

DPH 1,690.00 -24.00 (-1.40%)
price chart
Is Dechra Pharmaceuticals plc a better buy than GlaxoSmithKline plc after ...
Pharmaceutical giants Dechra Pharmaceuticals (LSE: DPH) and GlaxoSmithKline (LSE: GSK) took divergent paths in Monday morning business despite both releasing positive updates.
Dechra Pharmaceuticals PLC: Annual Results  PR Newswire (press release)
Dechra Pharmaceuticals PLC, Agrees Acquisition of US-based Putney, Inc for ...
Dechra Pharmaceuticals PLC (LSE: symbol DPH) announces the conditional acquisition of the entire share capital of Putney, Inc, a leading developer of generic companion animal pharmaceuticals in the US, based in Portland, Maine.
OP animal health parent leashes $200M acquisition  Kansas City Business Journal
Dechra to acquire Putney, maker of generic veterinary drugs, for $200 million  dvm360
Should You Buy Dechra Pharmaceuticals plc, Enquest Plc & Cairn Energy PLC Today?
Pet medicines mammoth Dechra Pharmaceuticals (LSE: DPH) cheered the market with terrific half-year numbers in Monday business, propelling the stock 8% higher from the end of last week.
Are RhythmOne plc, Dechra Pharmaceuticals plc and Pagegroup plc 'buys' after ...
Today's update from Pagegroup (LSE: PAGE) shows that the global recruitment company endured a somewhat mixed Q2. While its performance in southern Europe and Benelux was impressive with gross profit growth of 25% and 30% respectively, ...
Are Genus plc And Dechra Pharmaceuticals plc Better Buys Than GlaxoSmithKline plc?
While shares in GlaxoSmithKline (LSE: GSK) (NYSE: GSK.US) have disappointed in the last year, it has not been the same story for a number of its pharmaceutical rivals. In fact, shares in Genus (LSE: GNS) and Dechra (LSE: DPH) have soared in the last 12 ...
Should you be buying AstraZeneca plc, Alliance Pharma plc and Dechra ...
One of the major concerns of investors in AstraZeneca (LSE: AZN) in recent years has been its ability to pay dividends. That's because it has been subjected to a patent cliff, where a number of key drugs have come off-patent and with the company ...
Analysts Set Dechra Pharmaceuticals plc (DPH) Target Price at $1649.17
Dechra Pharmaceuticals plc logo Shares of Dechra Pharmaceuticals plc (LON:DPH) have been assigned a consensus recommendation of “Buy” from the eight research firms that are presently covering the stock.
Dechra Pharmaceuticals (LON:DPH) Broker Roundup  Fiscal Standard
Dechra Pharmaceuticals plc (DPH) Receives Consensus Recommendation of "Buy ...
Dechra Pharmaceuticals plc logo Dechra Pharmaceuticals plc (LON:DPH) has been assigned a consensus rating of “Buy” from the eight ratings firms that are currently covering the stock.
Dechra Pharmaceuticals plc (DPH) Given Average Rating of "Buy" by Brokerages
Dechra Pharmaceuticals plc logo Shares of Dechra Pharmaceuticals plc (LON:DPH) have been assigned a consensus rating of “Buy” from the eight brokerages that are presently covering the firm.
Dechra Pharmaceuticals plc (DPH) Rating Reiterated by Panmure Gordon  Transcript Daily
Dechra Pharmaceuticals plc (DPH) Price Target Raised to GBX 1890 at Numis ...  Markets Daily
Dechra Pharmaceuticals plc (LSE:DPH) Valuation in the Spotlight
Dechra Pharmaceuticals plc (LSE:DPH) has an ERP5 rank of 6837. The ERP5 Rank is an investment tool that analysts use to discover undervalued companies.